Pharma stocks drop despite limited impact from new U.S. drug tariffs
The post Pharma stocks drop despite limited impact from new U.S. drug tariffs appeared on BitcoinEthereumNews.com. Major drug company shares declined Friday after President Donald Trump announced 100% tariffs on imported branded medications, though analysts believe most large pharmaceutical firms will escape serious financial damage from these trade policies. Indian drug manufacturers experienced stock price decreases even as industry specialists indicated the tariffs would barely affect their business operations. Share values for Sun Pharmaceutical dropped 2.5% while Divi’s Laboratories fell 3.5% on Friday. The sector benchmark Nifty Pharma Index dropped over 2%. According to Sudarshan Jain, an official at the Indian Pharmaceutical Alliance, who spoke with CNBC, Indian firms primarily export generic medications to the United States, which means the anticipated impact should be quite limited. Yet investor anxiety seems rooted in a wider pattern of mounting trade disputes rather than immediate operational concerns. Broader trade tensions with India escalate Speaking to CNBC, Ayush Abhijeet, director of investments at White Oak Capital Partners, noted that international market observers interpret these tariffs as another chapter in recent economic pressures on India. The United States first introduced 25% tariffs on India during August, then raised these to 50% while citing India’s Russian oil purchases. White House trade advisor Peter Navarro called Russia’s conflict in Ukraine “Modi’s war.” Trade barriers have most severely affected Indian businesses in textiles, gems and jewelry, plus marine products. However, given that India’s economy depends largely on domestic spending, the overall tariff effects stay constrained. Last week, President Trump introduced a single-payment $100,000 fee for new H-1B visa applications, a policy that may disproportionately impact Indian technology workers. This series of quick policy announcements has heightened investor anxiety, with many concerned about additional escalation from Washington. Gyanendra Tripathi, partner at risk advisory firm BDO Partners, believes these sequential U.S. measures could represent bargaining strategies designed to accelerate trade negotiations with India. At the same…
The post Pharma stocks drop despite limited impact from new U.S. drug tariffs appeared on BitcoinEthereumNews.com.
Major drug company shares declined Friday after President Donald Trump announced 100% tariffs on imported branded medications, though analysts believe most large pharmaceutical firms will escape serious financial damage from these trade policies. Indian drug manufacturers experienced stock price decreases even as industry specialists indicated the tariffs would barely affect their business operations. Share values for Sun Pharmaceutical dropped 2.5% while Divi’s Laboratories fell 3.5% on Friday. The sector benchmark Nifty Pharma Index dropped over 2%. According to Sudarshan Jain, an official at the Indian Pharmaceutical Alliance, who spoke with CNBC, Indian firms primarily export generic medications to the United States, which means the anticipated impact should be quite limited. Yet investor anxiety seems rooted in a wider pattern of mounting trade disputes rather than immediate operational concerns. Broader trade tensions with India escalate Speaking to CNBC, Ayush Abhijeet, director of investments at White Oak Capital Partners, noted that international market observers interpret these tariffs as another chapter in recent economic pressures on India. The United States first introduced 25% tariffs on India during August, then raised these to 50% while citing India’s Russian oil purchases. White House trade advisor Peter Navarro called Russia’s conflict in Ukraine “Modi’s war.” Trade barriers have most severely affected Indian businesses in textiles, gems and jewelry, plus marine products. However, given that India’s economy depends largely on domestic spending, the overall tariff effects stay constrained. Last week, President Trump introduced a single-payment $100,000 fee for new H-1B visa applications, a policy that may disproportionately impact Indian technology workers. This series of quick policy announcements has heightened investor anxiety, with many concerned about additional escalation from Washington. Gyanendra Tripathi, partner at risk advisory firm BDO Partners, believes these sequential U.S. measures could represent bargaining strategies designed to accelerate trade negotiations with India. At the same…
What's Your Reaction?
